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Abstract
Mycobacterium avium subsp. paratuberculosis (MAP) is the causative agent of Johne’s dis-
ease (JD), a chronic intestinal inflammatory disease of cattle and other ruminants. JD has a
high herd prevalence and causes serious animal health problems and significant economic
loss in domesticated ruminants throughout the world. Since serological detection of MAP
infected animals during the early stages of infection remains challenging due to the low sen-
sitivity of extant assays, we screened 180 well-characterized serum samples using a whole
proteome microarray from Mycobacterium tuberculosis (MTB), a close relative of MAP.
Based on extensive testing of serum and milk samples, fecal culture and qPCR for direct
detection of MAP, the samples were previously assigned to one of 4 groups: negative low
exposure (n = 30, NL); negative high exposure (n = 30, NH); fecal positive, ELISA negative
(n = 60, F+E-); and fecal positive, ELISA positive (n = 60, F+E+). Of the 740 reactive pro-
teins, several antigens were serologically recognized early but not late in infection, suggest-
ing a complex and dynamic evolution of the MAP humoral immune response during disease
progression. Ordinal logistic regression models identified a subset of 47 candidate proteins
with significantly different normalized intensity values (p<0.05), including 12 in the NH and
23 in F+E- groups, suggesting potential utility for the early detection of MAP infected ani-
mals. Next, the diagnostic utility of four MAP orthologs (MAP1569, MAP2942c, MAP2609,
and MAP1272c) was assessed and reveal moderate to high diagnostic sensitivities (range
48.3% to 76.7%) and specificity (range 96.7% to 100%), with a combined 88.3% sensitivity
and 96.7% specificity. Taken together, the results of our analyses have identified several
candidate MAP proteins of potential utility for the early detection of MAP infection, as well
individual MAP proteins that may serve as the foundation for the next generation of well-
defined serological diagnosis of JD in cattle.
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Introduction
Johne’s disease (JD) is a chronic granulomatous intestinal inflammatory disease that results
from infection with Mycobacterium avium subspecies paratuberculosis (MAP) [1]. JD results in
more than $200 million in annual losses to the US dairy industry each year [2]. Despite consid-
erable control efforts, JD remains a major problem for producers and the industry due to high
prevalence rates (68% of all US dairy herds and 95% of those with over 500 cows have at least
one JD positive animal) [3]. Although animals are infected early in life through ingestion of
bacilli via the fecal-oral route or from colostrum, JD takes several years to manifest [4, 5]. Dur-
ing this extremely long sub-clinical phase, infected animals are continuously or intermittently
shedding the pathogen into the environment and spreading the disease. However, it is very dif-
ficult to reliably identify infected from non-infected animals during early infection, especially
in animals that are intermittently shedding. Hence, the development of highly sensitive and
specific diagnostics has the potential to be transformative in the field and is key for control of
JD and enhancement of animal health.
Due to low sensitivity of current serological assays (particularly ELISAs) which use rela-
tively crude cellular extracts, several studies focused on identification of individual antigens
soon after the complete genome sequence of MAP was published [6]. These include studies
that used bioinformatics’ screens to predict function and localization of proteins, followed by
proteomic analyses of cell wall associated proteins [7]; MAP culture filtrates [8]; surface pro-
teins expressed in macrophage [9]; proteins that respond to stress during in vitro culture [10];
proteomic comparison of MAP with Mycobacterium aviam subspecies avium [11]; as well as a
dot-blot based protein arrays of recombinant proteins representing secreted or cell wall as-
sociated proteins [12] to identify MAP antigens of potential diagnostic utility with varying
degrees of success. For instance, studies have shown that sera from experimentally infected cat-
tle recognized specific MAP proteins at a very early stage of the infection, or with either mild
or paucibacillary infections that were presumably from subclinical animals and well before
antibodies were detected by using commercial ELISA assays [13–15], suggesting that a subset
of MAP proteins may be seroreactive during early (subclinical) infection. However, none of
these candidates have proved of clinical utility or have shown potential to replace the extant
whole-cell antigen based commercially available ELISAs.
To date, more than 200 recombinant proteins have been tested for antigenicity and more
than 800 recombinant proteins have been overexpressed for antigen discovery [12–16]. How-
ever, this represents only approximately 20% of predicted proteins in the MAP proteome
(n = 4,350) [6]. Given the significant time and financial costs associated with cloning, express-
ing and purifying additional proteins from MAP, we have recently explored the possibility
of leveraging the commercially available whole proteome microarray from Mycobacterium
tuberculosis (MTB), a closely related pathogen [17]. The MTB proteome array contains ~4,000
features (3,864 unique MTB genes) covering 97% of the genome and has previously been suc-
cessfully used to identify biomarkers of active TB infection from a global collection of human
and non-human primate serum and plasma samples [18, 19]. Our preliminary pairwise com-
parison of amino acid sequence between orthologous proteins in MAP and MTB showed an
average of 62% identity (range 19% to 100%) with more than half sharing >75% identity [17].
Further bioinformatic analyses confirmed that the MTB proteome array contains ~800 MAP
orthologs that have previously been expressed and an additional ~1,900 having significant lev-
els of homology with their MAP orthologs that have not been expressed.
Our pilot studies conducted using serum samples from 9 MAP-infected cows (6 clinical
and 3 subclinical) and 3 uninfected control and MTB full-proteome chips revealed more than
700 MTB reactive antigens [17], less than 200 of which represent orthologs that were already
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represented among the expressed MAP proteins. Probing the MTB array with serum from
MAP-infected animals resulted in the identification of more than 500 antigens, for which sev-
eral of these proteins displayed greater reactivity with serum from subclinical animals as com-
pared to clinical stage animals. This suggests that the MTB protein array has considerable
potential to identify a significant number of new candidate antigens detectable during early
stages of disease. However, only a very small number of serum samples were used in this pre-
liminary screen, and hence these results needed to be corroborated with an expanded set of
well-characterized samples, and further validated for use in immunoassays. We here report
immune profiling using a large collection of well-characterized serum samples from MAP-
infected cows and negative controls with the MTB protein microarray, as well as the develop-
ment of specific and sensitive ELISA assays using defined MAP antigens.
Materials and methods
Bovine serum samples
All serum samples were collected as part of the Johne’s Disease Integrated Program (JDIP,
http://mycobacterialdiseases.org) diagnostic standards sample collection project. In brief, the
180 samples used in these studies were collected from cows housed in 13 dairy farms from 4
states: California, Georgia, Minnesota, and Pennsylvania (S1 Table). The herd size ranged
from 66 to 1,400 and prevalence of JD ranged from 0 to 53.30% based on serum ELISA tests
conducted prior to sample collection. All herds were negative for bovine TB. As JDIP diagnos-
tic standards sample collection study designed, each cow was tested for level of MAP shedding
in feces as well as serological reactivity. MAP shedding was determined by fecal culture using
Herrold’s solid medium (HEYM) and two different liquid culture medium systems, BACTEC
MGIT and Trek (Becton, Dickinson and Company, Franklin Lakes, NJ); all fecal cultures were
confirmed by acid fast staining and PCR. Fecal qPCR was performed for each animal with the
LT TaqMan (ThermoFisher, Waltham, MA) and Tetracore (Tetracore, Rockville, MD) assays.
Serum and milk ELISA tests were performed using both IDEXX kit (IDEXX Laboratories,
Inc., ME) and ParaChek (ThermoFisher, Waltham, MA) according to the manufacturers’
instructions. Based on the result of fecal and serological tests, cows were stratified into three
groups: both fecal and serological tests negative (n = 60), fecal test positive and serological test
negative (F+E-, n = 60) and both fecal and serological tests positive (F+E+, n = 60). Based on
the previously observed prevalence of JD in each originating farm (according to serological
tests conducted one year before above samples collected), cows in the negative group were fur-
ther stratified into two groups: negative from low-exposure herds (NL, n = 30) if they were
from farms that had no recent evidence of JD prevalence (0%) and negative from high-expo-
sure herds (NH, n = 30) if the farm had evidence of previous JD prevalence (0.60 to 53.30%).
All serum samples were collected as part of the Johne’s Disease Integrated Program (JDIP,
http://mycobacterialdiseases.org) diagnostic standards sample collection project number
2008-55620-18710. Animal use protocols were approved by the Pennsylvania State University
IACUC numbers 34625 and 43309.
Microarray fabrication and probing
The MTB microarray fabrication and probing were conducted in Antigen Discovery Inc. (ADI,
Irvine, CA) as described previously [18, 19]. The microarrays carried 3,963 MTB protein spots,
which corresponded to more than 97% of the ORFs in the MTB H37Rv genome [18]. Briefly,
using genomic DNA as a template, all open reading frames in the MTB H37Rv genome were
amplified using custom PCR primers. Genes> 3kb in length were amplified as overlapping
fragments. PCR products were cloned into a linearized T7 vector using in vivo recombination
Early diagnosis of Johne’s disease
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cloning. Using individually purified plasmids, MTB proteins were expressed in an E. coli-based
in vitro transcription and translation system (IVTT) (5 Prime, Gaithersburg, MD). The resulting
IVTT reactions were printed as single spots without further purification into custom 3-pad
nitrocellulose-coated Oncyte Avid slides (Grace Bio-Labs, Bend, OR) using an Omni Grid 100
microarray printer (Digilabs, Inc., Marlborough, MA) in 4x4 sub-array format, with each subar-
ray comprising 18x18 spots. Each sub-array included negative control spots carrying IVTT reac-
tions without DNA templates, purified proteins spots of previously identified MTB biomarkers,
as well as positive control spots for the hybridization. Quality control was carried out by probing
a sample of chips from each print run using a monoclonal antibody against the N-terminal
polyhistidine tag, the C-terminal HA tag and selected reference serum. Cryopreserved serum
samples were thawed on ice and pre-incubated with E. coli lysate to absorb anti-E. coli and
cross-reactive antibodies. Prior to incubation with serum, slides were re-hydrated and blocked
for 30 minutes using Blocking Buffer (Main Manufacturing, Sanford, ME). Serum samples were
diluted 1:200 and incubated on arrays at 4˚C overnight with gentle agitation. Bound IgG antibod-
ies were detected with a biotinylated anti-bovine IgG secondary antibody (Jackson ImmunoRe-
search, West Grove, PA), followed by incubation with Surelight-P3 fluorochrome conjugated to
streptavidin (Columbia Biosciences, Columbia, NY). Slides were then dried and scanned in a
Genepix 4300A microarray scanner (Molecular Devices, San Diego, CA). The scanner laser power
and PMT gain were calibrated daily to intensities obtained from reference sera to control for day-
to-day variation. Fluorescence intensity values for each spot were quantified using GenePix Pro
software, and data were exported in comma separated values (CSV) format (intensity data accessi-
ble via https://scholarsphere.psu.edu/concern/generic_works/hhm50ts37m).
Data analysis
The intensity data files in CSV format were read, processed and analyzed using an automated
data analysis pipeline developed at ADI that was implemented in R (www.r-project.org). Spot
intensity measurements were converted into a single data matrix of local background-sub-
tracted intensities. The row names of the data matrix are unique spot identifiers that link to a
spot annotation database, and the column names are unique sample identifiers that link to a
sample information database. For each sample, quality checks were performed for possible
missing spots, contaminations and unusual background variation. The data were also in-
spected for the presence of subtle systematic effects and biases (probing day, slide, pad, print
order, etc). Once the data passed quality assurance, the final dataset utilized for analysis was
obtained by the following steps: (1) log2 transformation of raw intensities; (2) for each sample,
calculation of the median of the IVTT negative control spots; and finally (3) subtraction of the
sample-specific IVTT negative control medians. An antigen is classified as highly reactive to a
given sample if its normalized intensity value is greater than 0.5 (the raw intensity is at least
approximately1.4x the sample’s median IVTT negative control). An individual’s antibody
breadth scores are determined by its count of reactive antigens. Antibody breadth profiles
were compared between groups using Poisson regression. Normalized data were modeled
using parametric and non-parametric tests for between-group comparisons. For complex data
sets, comparisons were made using multivariate linear regression or linear mixed models with
random effects for longitudinal data. All p-values were adjusted for the false discovery rate as
previously described [20].
ELISA assay for selected MAP recombinant proteins
ELISA assays were conducted for selected MAP recombinant proteins (their MTB orthologs
were identified as significantly reactive antigens) with serum samples from NL and F+E
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+ groups. The procedure was adapted from our previously described protocol [17] with a
minor modification. ELISA 96-well microplates were coated with 50 μl/well of 1 μg/ml recom-
binant MAP protein or 0.5 μg/ml MBP/LacZ (fusion protein from cloning vector) in carbon-
ate/bicarbonate buffer 0.1 M pH 9.6. Plates were sealed and incubated overnight at 4˚C, then
washed three times with 1xPBS, pH 7.4 containing 0.1% Tween 20 (PBS-T). Wells were
blocked by adding 200 μl/well of PBS-T containing 1% bovine serum albumin (PBS-T-BSA)
and incubated at room temperature for 1 hour before washing the plate three times with
PBS-T. Serum samples diluted 1:250 in PBS-T-BSA were added to each well (100 μl/well) and
incubated at room temperature for 1 hour before washing six times with PBS-T. Then 100 μl/
well of anti-goat IgG peroxidase conjugate (Vector Labs, Buringame, CA, USA) diluted
1:10,000 in PBS-T-BSA was added to all wells and incubated at room temperature for 1 hour
before the plates were again washed six times with PBS-T. Finally, 100 μl/well of tetra methyl-
benzidine (TMB) SureBlue solution (KPL, Gaithersburg, MD, USA) was added and the reac-
tion incubated for 10–15 minutes at room temperature with no light, before the reaction was
stopped with 100 μl/well of 1.0 N HCl solution. The spectrophotometric reading of all wells
was performed at 450 nm using a PowerWave XS2 microplate reader (BIoTek, Winooski, VT,
USA). The OD value of each sample was normalized by sample OD–MBP/LacZ OD to elimi-
nate the non-specific background produced by anti-MBP/LacZ in each serum sample. The
group t test was performed using GraphPad software (https://www.graphpad.com) and the sig-
nificance of correlation of coefficient was determined using an online statistical computation
tool (http://vassarstats.net/index.html).
Logistic regression analysis
To determine which antigens had significantly different normalized intensities values among the
4 groups (NL, NH, F+E-, F+E+), ordinal logistic regression models were fitted, using PROC
LOGISTIC in SAS (version 9.2, 2009; SAS Institute Inc., Cary, NC). Such models are appropriate
for outcomes with more than two categories, as in this study, where the outcome was group with
4 categories (NL, NH, F+E-, F+E+). Each antigen was included in a model one at a time; all mod-
els also included lactation number of the cow, day-in-milk, and herd size. In each model, the gen-
eralized logit function was specified; each nonbaseline category is compared to the baseline
category. In each model run, 180 observations were read in, but only 167 were used in the analysis,
due to missing values for some covariates. Statistical significance was considered at alpha = 0.05.
The output produced was in the form of odds ratios and their 95% confidence limits, for
each category of group within a covariate (antigen, lactation number, day-in-milk, herd size).
The baseline category varied with model, as it was desirable to have the baseline odds ratio value
for each antigen be 1.0, and all comparisons made to that, within each antigen of interest, such
that all comparison values were greater than 1.0. Therefore, each comparison (odds ratio for a
particular group) gave the odds of belonging to a particular group compared to the odds of
belonging to the baseline group. The odds ratio indicates how likely a certain antigen is associ-
ated with a particular group, compared to being associated with the baseline group. Another
way to view the findings is thus: if, for a particular antigen, the odds ratio for NL is 1.0 (baseline
group) and the odds ratio for F+E+ is 2.5, then for each unit increase in the normalized intensity
value of the antigen, a cow is 2.5 times more likely to be classified as F+E+ than as NL.
Results
Identification of highly reactive proteins
A total of 740 highly reactive antigens were identified based on normalized intensities at a 10%
threshold with a distribution amongst the NL, NH, F+E-, and F+E+ groups as shown in the
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Venn diagram (Fig 1A). In brief, the four ellipses show the total number of hits from the four
groups of animals, with the majority of reactive proteins sharing cross-reactivity. If a highly
reactive protein was identified in one group only, the protein was categorized as a unique pro-
tein. If a reactive protein was identified in two or more groups, the protein was categorized as
a shared protein. Proteins were divided into 15 categories based on their unique or shared sta-
tus among the groups. Unique proteins were identified in each of the 4 groups as: 38 in NL
(5.1%), 35 in NH (4.7%), 33 in F+E- (4.5%) and 30 in F+E+ (4.1%) group respectively. There
were a total of 411 proteins shared among all 4 groups, accounting for 55.5% of the total reac-
tive proteins identified. The remaining proteins were shared within two (12.3%) or three
(13.8%) of the groups. The average normalized intensities of proteins shared by all 4 groups
were highest (> 1.0), while the average intensities of the other groups were between 0.37 and
0.67 (Fig 1B).
Identification of significantly reactive proteins
To determine which of the two groups of negative samples should be used as reference for
group comparisons (NL or NH), we compared the mean intensities of the infected groups (F
+E- and F+E+) with that of NL and NH individually as a reference. When mean intensities of
the NL group were used as reference, 39 and 76 proteins were identified as significantly reac-
tive proteins (P<0.05, based on group t test) in the F+E- and F+E+ groups, respectively. How-
ever, when the mean intensities of the NH group were used as reference, the number of
significantly reactive proteins was reduced to 12 and 26 in the F+E- and F+E+ groups, respec-
tively (S1A and S1B Fig). There were only 5 proteins shared in F+E- and 15 in F+E+ groups
when mean intensities of NL and NH were used as a reference, respectively. In light of these
observations, we chose to use NL alone as a reference for two reasons: 1) antigen identification
was very reference-dependent and 2) samples from animals early in infection may contain
Fig 1. Highly reactive proteins identified in MTB microarray. (A) Venn diagram at 10% threshold shows
antigen hit number distribution of all 4 groups: negative low exposure (NL), negative high exposure (NH), fecal
positive & ELISA negative (F+E-), and fecal positive & ELISA positive (F+E+). The four ellipses show the total
number of hits from four groups and majority antigens are shared among 4 groups. The non-overlapping parts
of the 4 ellipses represent the unique antigens for each group. (B) Serological reactivity in selected groups.
Normalized mean intensities in each group on unique and shared antigens. The height of bars represents the
mean intensity. Standard error bars are added to each column.
https://doi.org/10.1371/journal.pone.0184373.g001
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antibodies recognizing MTB antigens in NH, and therefore candidate antigens may not be rec-
ognized if the mean intensities of NH are used as a reference. Mean normalized intensities in
each group were compared to NL with a two-tailed t-test using a p-value< 0.05 for signifi-
cance. Of the 740 highly reactive proteins from the MTB array, approximately 13% were iden-
tified as significant (100 proteins) using this test. Among the 100 identified MTB proteins,
there were a total of 69 unique proteins in the groups (9 in NH, 13 in F+E-, and 47 in F+E+)
and 31 shared among groups (S2 Fig). On the other hand, if the mean intensities of proteins
were significantly higher in the NL-alone group or groups shared with NL compared to the
other three groups, these proteins were not considered as significant antigens, or “hits” (Fig
1B). Significant antigens were identified in the following groups (number of significant anti-
gens/total in group; percentage of significant antigens in the group): NH alone (5/35, 13.8%),
NH/F+E- (1/12, 8.3%), NH/ F+E+ (8/23, 34.8%), NH/F+E-/F+E+ (21/51, 41.2%), F+E- alone
(6/33, 18.2%), F+E-/F+E+ (10/25, 40.0%) and F+E+ alone (11/30, 36.7%).
Patterns of intensity changes among three groups
Compared to the normalized mean intensity of each protein in NL, there were 27 proteins
with significantly higher and 15 with significantly lower intensities identified in the NH group
(P< 0.05). For the majority of proteins, the trend of intensity changes in the NH group was
consistent with the changes in infected groups. For example, up to two thirds of proteins iden-
tified in NH were also found to have significantly higher (or lower) intensities in F+E- or F+E
+ or both groups (S2 Fig) when compared with NL. Similar to NH, two thirds of the proteins
identified in F+E- group were also shared with other groups, while in F+E+ group, more than
60% of proteins were unique. There were 6 patterns of intensity changes among three groups
in comparison with NL (Fig 2). The first pattern shows mean intensities are significantly
higher only in NL (Fig 2A). Among the 15 proteins with significantly lower intensities in
NH, 14 were also found with lower intensities in F+E- and F+E+ groups. Only one protein,
Rv0040c (Fig 2E; ortholog MAP0047c), showed significant lower intensities in NH and F+E-,
but significantly higher intensities in F+E+. Compared to intensities in NL, the proteins with
lower intensities in infected groups were not considered reactive antigens, while proteins with
significantly higher intensities in the other three groups were considered reactive antigens
following the described 5 patterns. Proteins with significantly higher intensities only in NH
group (Fig 2B) were considered to be antigens recognized only during the early stage of infec-
tion. Proteins with significantly higher intensities only in F+E- (Fig 2C) or only in F+E+ (Fig
2D) indicate that the antigen is recognized only in the middle or late stages of infection, while
Fig 2. Patterns of mean intensities in each group. The red square markers represent mean intensities
significantly higher than that in NL and blue triangle markers indicate mean intensities significantly lower than
that of NL. Standard error bars are added to each spot. Mean intensities are significantly higher: A. in NL; B. in
NH; C. in F+E-; D. in F+E+; E. in F+E- and F+E+; F. in all three groups including NH, F+E-, and F+E+ (Y axis:
mean intensity of each group).
https://doi.org/10.1371/journal.pone.0184373.g002
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proteins with significantly higher intensities in both F+E- and F+E+ groups (Fig 2E) or in all
three groups including NH, F+E- and F+E+ (Fig 2F), indicate antigens that can be recognized
throughout the course of infection.
Orthologs in MAP
Among the 100 significantly reactive MTB proteins, there were 91 proteins with mean intensi-
ties close to or higher than 0.5 and 9 proteins with intensities lower than 0.5. Normalized
intensities at 0.5 indicated an approximately 41% higher signal than background where 0 rep-
resents the equivalence with background intensities. Among these 9 proteins, mean intensities
in the NL group were near 0 and mean intensities in infected groups were more likely to be sig-
nificantly higher even mean intensities are slightly increased when compared to NL. Therefore,
these 9 proteins were excluded to avoid false positives. For the remaining 91 proteins identified
in the MTB array, the MAP orthologs were determined based on the comparison of their
amino acid sequences and the patterns of antigenicity between the MTB protein identified on
the array and the corresponding MAP ortholog. Specifically, for a MAP protein to be consid-
ered an ortholog of the identified MTB protein, the amino acid sequence identity must
be 40%. However, some proteins, such as Rv0304c-s1 and MAP0210c, which have an overall
low identity but show a higher identity in the antigenic regions, are also considered to be MAP
orthologs. While the majority of MTB proteins match one single MAP protein, in some cases
there are two or more MTB proteins matching the same MAP ortholog, such as Rv0304c &
Rv1004c to MAP0210c; Rv1677 & Rv2878c to MAP2942c; Rv1651c & Rv2328 to MAP4144.
MAP orthologs were selected from the infected groups based on percent sequence identity and
mean intensity values of corresponding MTB proteins on microarrays. For instance, 5 MTB
proteins (Rv1753c, Rv0442c, Rv1918c, Rv1917c, and Rv3350c) match MAP3939c with identi-
ties ranging from 58.2% to 72.2% at the amino acid level (S3A Fig). These 5 MTB orthologs are
PPE family proteins with an identity between 49% and 71% between each other. However,
Rv0442c is the most closely related ortholog with an amino acid sequence identity of 72.2%
and the highest mean intensity. The MAP3939c and Rv0442c also showed similar antigenicity
patterns (S3 Fig and Fig 3B). A total of 73 MAP orthologs were determined from initial 100
significant MTB antigens identified from MTB array. The logistic regression analysis was
applied to 73 MTB ortholgs and ordinal logical regression models were fit. In each model the
baseline has an odds ratio of 1.0, and all the other categories have odds ratios greater than 1.0,
compared to the baseline. Among 73 proteins, there are 47 proteins having significantly differ-
ent normalized intensity values in at least one group (p<0.05). The remaining 26 antigens did
not significantly differ in any of the 4 groups and were excluded as antigens. The 47 antigens
were visualized in the heatmap showing the odds ratios for serum reactivity to each antigen
among 4 groups (Fig 3). S2 Table listed all 47 MAP proteins with the identity to their MAP
orthologs, predicted cell location, functional description, and odds ratios among 4 groups (S2
Table).
Recognition of identified reactive antigens in previous studies
Several MAP orthologs that were identified in the MTB microarray were also recognized in
previous studies by other researchers. For instance, the orthologs MAP2609, MAP2942, and
MAP0210c were previously characterized as secreted 9, 15, and 34 kDa MAP antigens, which
were recognized by antibodies from naturally infected cattle at both clinical and subclinical
stages [21]. The ortholog MAP1569 (ModD) was also identified as a secreted protein that was
recognized by sera collected from naturally infected cows [22, 23]. The ortholog MAP0834c, a
two component system transcriptional regulator, was recognized by sera from naturally MAP
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infected sheep as a significantly reactive antigen [24]. Another ortholog MAP1272c, an inva-
sion-associated protein, has been identified in several studies as one a promising antigen [24,
25] and recently further characterized on crystal structures, combined with functional assays
[26]. The ortholog MAP0900 (P35), a conserved membrane protein, was recognized by 100%
of animals including cattle, goats and sheep with Johne’s disease in the clinical stage and 75%
of cattle in the sub-clinical stage [27], as well as 75% of patients with Crohn’s disease [28]. One
protein, Rv1411c (ortholog MAP1138c), significantly reactive in F+E+ group but not listed as
identified MAP orthologs due to low mean intensities (<0.5), was also recognized in previous
studies as immunogenic [29]. Antibody to expressed recombinant protein MAP1138c (P22)
was detected in sheep vaccinated by a MAP strain and also in clinical/subclinical cows with
Johne’s disease [29]. The recombinant P22 (MAP1138c) was able to stimulate significant IFN-
γ production in blood of P22-immunized sheep [30]. It needs to be noted that all of the above
proteins in previous studies were tested in a relatively small number of infected animals and
the majority of animals were tested positive with commercially available ELISA tests. About
90% of identified orthologs with the MTB microarray assays in this study have never been
tested for their serological reactivity on a large scale set of serum samples.
Sensitivity and specificity of identified top antigens
Our goal was to establish a collection of antigens that could be used as a multiplex set to accu-
rately distinguish MAP-infected animals from non-infected animals. To do this, we compared
the sensitivity and specificity for each of the 73 identified proteins at both mean + 1 standard
deviation (1SD) and mean + 2SD level (S3 Table). Specificity at the M+1SD cutoff is between
63.3% and 93.3% with a median of 83.3%, and increased to 73.3% to 100.0% with a median of
96.7% at the M+2SD cutoff. Sensitivities for the majority of single proteins were low with
median sensitivities of 33.3%, 28.3%, and 30.5% at M+1SD cutoff in NH, F+E-, and F+E
+ groups, respectively, and further reduced to 16.7%, 16.7%, and 15.0% at the M+2SD cutoff.
Based on comparison of odds ratio and sensitivity/specificity for each protein, we focused on
proteins with relatively high sensitivity/specificity and compared different combinations of
Fig 3. Patterns of serum reactivity to MTB proteins with their odds ratios that differed significantly in
at least one of the 4 groups. The heatmap shows the odds ratio of the serum reactivity from 4 groups to
each of the 47 proteins. Each column represents one protein, odds ratios (rows) are visualized as a color
spectrum. The heatmap was generated using the ComplexHeatmap package in R. The clustering was
performed using the pvclust package with multiscale bootstrap resampling. Arguments passed to the pvclust
command for the hierarchical clustering method (method.hclust) was “median” and for the distance method
(method.dist) was “maximum”. The confidence intervals were overlaid on the heatmap using the ggplot2
package.
https://doi.org/10.1371/journal.pone.0184373.g003
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several proteins to find the best combination with high sensitivity without significantly lowering
specificity. For each of group NH, F+E-, and F+E+, we selected a combination of 4 proteins. At
the M+1SD cutoff, the sensitivity with the 4 combined proteins significantly increased and
reached 80.0%, 85.0%, and 88.3% in the NH, F+E-, and F+E+ groups respectively, however, the
specificity dropped from above 90.0% with a single protein to 43.3% and 73.3%, respectively. To
avoid false positives, we chose a cutoff at M+2SD level and the sensitivity at each group signifi-
cantly increased with specificities all above 80.0% (Fig 4). These results indicate that using a
combination of antigens greatly increases the sensitivity in detecting MAP with only a relatively
small reduction in specificity.
Reactivity of MAP orthologs confirmed on ELISA
To evaluate if antigens identified with the MTB protein microarray are reactive in infected
cows, four recombinant proteins of MAP orthologs (MAP1569, MAP2942c, MAP2609, and
MAP1272c corresponding to Rv1860, Rv2878c, Rv1174c and Rv1566c) were selected for
ELISA with 90 serum samples including 30 from NL and 60 from F+E+. The identities of these
four orthologs between MAP and MTB are from 61.8% to 77.6%. The normalized OD values
in two groups were compared and OD values in F+E+ group were significantly higher than
that in NL group with p< 0.01 for all 4 antigens (Fig 5A). This result was consistent with the
group comparison in MTB protein array, but the background was much lower in NL group,
and the ratio of positive/negative was greatly increased in the MAP ELISA. Correlation
between the seroreactivity of antigens on the MAP ELISA and orthologs on the MTB array
was also examined. For each serum sample, the normalized OD on MAP ELISA was compared
to intensity on MTB array and the correlation coefficient, Pearson’s rho, was from 0.395 to
0.796 with the lowest in MAP1569 and the highest in MAP2942c (p value< 0.0001 in each of
the antigens). Fig 5B showed correlation among all 4 proteins (rho = 0.653, p < 0.0000001),
indicating strong correlation between serological reactivity of infected cows to MTB antigen
and MAP orthologs. These data suggest that MTB orthologs on the MTB arrays react to serum
from MAP-infected cows in a manner similar to MAP ELISA with MAP recombinant pro-
teins. Based on ELISA data, the sensitivity and specificity for detection of infection was exam-
ined and compared with that in MTB protein array at M+1SD and M+2SD cutoff levels. At M
+1SD cutoff, the sensitivity on each individual antigen ranged from 55.0% to 81.7% with speci-
ficity 83.3% to 96.7%. With 4 antigens combined, the sensitivity increased to 96.7%, but speci-
ficity was reduced to 70.0%. At M+2SD cutoff, although sensitivity of each individual antigen
was reduced (48.3% - 76.7%), the specificity ranged from 96.7% to 100%. With 4 antigens
Fig 4. Increased sensitivities with antigen combinations. Columns filled with blue color represent
specificity (%) and columns filled with green, yellow, and crimson represent sensitivity (%) in NH, F+E-, and F
+E+ groups. Columns filled with solid color indicate individual protein and columns filled with texture indicate
combined proteins.
https://doi.org/10.1371/journal.pone.0184373.g004
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combined, sensitivity increased to 88.3% with specificity 96.7%. Compared to the MTB array
on these 4 antigens, MAP ELISA displayed higher sensitivity and specificity. The consistency
of group comparison and strong correlation between MTB array and MAP ELISA indicate
that antigenic orthologs identified on MTB protein array with serum samples from cows are
capable of distinguishing infected cows from uninfected cows.
Discussion
Generally, determination of significantly reactive antigens for recombinant proteins is based
on the comparison of serological reactivity of infected animals to uninfected animals. Usually,
when an animal tests MAP negative for both fecal (culture or PCR) and ELISA (serum or
milk), we consider the animal to be not infected. However, in this case, the uninfected status
may not be true because MAP infection at the tissue level is unknown. Several studies have
shown that cattle determined not to be shedding based on either fecal culture or PCR were
later found to be MAP-infected in their tissues at the slaughterhouse. Whitlock et al. reported
that more than 30% of fecal culture negative cattle from moderately infected herds (fecal cul-
ture positive ranging between 5% and 15%) have infected tissues taken at the time of slaughter
[31]. Another study comparing MAP culture and PCR in fecal and tissue samples from intes-
tine and the mesenteric lymph node found that MAP was detected by PCR and isolated from
tissues in some cattle testing fecal negative [32]. A recent study compared the lymphatic fluid,
fecal material, and antibodies from serum and milk samples (ELISA) for detection of MAP
infection in cows. The results showed that more than two thirds of animals with a positive
Fig 5. Reactivity of MAP orthologs on ELISA. A. Group comparison between NL and F+E+ in selected
MAP recombinant protein ELISA. B. Correlation between MAP ELISA and MTB protein array. C. Sensitivity
and specificity with individual MAP recombinant protein and combined 4 proteins at M+2SD cutoff.
https://doi.org/10.1371/journal.pone.0184373.g005
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lymph result were negative in all fecal and ELISA tests and only 7% of the animals with positive
lymph-PCR were also positive in all other tests [33]. Taken together, these results indicate that
some animals with negative fecal and ELISA tests are not a true negative.
In this study, 60 samples with both fecal and ELISA negative results were divided into two
groups, NL and NH, according to the prevalence of the farms where the samples were col-
lected. By comparing the means of normalized intensities between these two groups, we identi-
fied 27 proteins with significantly higher reactivity. Among the 27 identified proteins, two
thirds were also shared with F+E-, F+E+, or both, indicating the proteins identified in NH are
likely to be true antigens. We hypothesized that cows in the NH group may not be true nega-
tives and were probably in early stage of infection. We found that if NH was used for reference,
only 31% and 34% of reactive antigens were identified in the F+E- and F+E+ groups respec-
tively, as compared when NL was used as a reference. Because it is important to select true neg-
atives as a reference to identify reactive antigens in the infected groups of animals we analyzed
our data set using NL as the reference.
We hypothesized the stages of infection in the cows as follows; NL = Uninfected; NH =
Early; F+E- = Middle; and F+E+ = Late stage of infection. There is no significant difference in
average lactation number among the 4 groups: NL is 3.13 (SD = ±1.46), NH 2.93 (SD = ±1.08),
F+E- 2.95 (SD = ±1.06), F+E+ 3.32 (SD = ±1.40) (S1 Table). All infected cows are likely to be
in the sub-clinical stage because there were no clinical signs of Johne’s disease recorded. As
mentioned above, NH showed a different profile of serological reactivity to recombinant pro-
teins compared to NL despite the negative results from the fecal exam and commercial ELISA.
Therefore, we speculated that cows in NH were infected with MAP at the early stage. At this
stage, serological reaction with traditional commercial ELISA is unlikely to be detected accord-
ing to experiments in cows with established MAP infection. The time required for seroconver-
sion in experimentally infected calves detectable by commercially available ELISAs is between
10 and 28 months [34]; and it may take possibly longer in naturally infected animals. Although
animals generally shed MAP in their feces before seroconversion, the chance of detecting
MAP shedding at this stage is very low due to intermittent shedding as observed in many
experimentally infected animals [35]. A comparative investigation on cows in slaughterhouses
demonstrated viable MAP (or MAP DNA) isolated from mesenteric lymph nodes and intesti-
nal tissues but not from feces in some cows [32], indicating that negative fecal tests could not
exclude infection in gut tissue. The other two infected groups, F+E- and F+E+, were both posi-
tive in fecal testing, with or without positive ELISA, but the bacterial burden in feces was sig-
nificantly different (P<0.001). According to two fecal qPCR tests, the average Ct values in
F+E- were 35.6 (SD = ±2.7) and 37.7 (SD = ±2.5), compared to 26.7 (SD = ±4.1) and 29.8
(SD = ±4.2) in F+E+, indicating that the MAP burden in the F+E+ group was at least 100
times higher than the F+E- group. The cows in F+E- were considered to be low shedders while
the F+E+ group contained high shedders. Based on the quantity of fecal MAP shedding and
serological reactivity (ELISA) results, it is reasonable to assign cows in the F+E- group as mid-
dle stage infection and the F+E+ group as late stage infection. In previous studies, cows have
usually been classified as negative, sub-clinical, and clinical. In this study, we further divided
sub-clinical into early, middle, and late stages and identified unique and shared reactive anti-
gens at these different stages of infection.
Currently available ELISA methods are not able to detect serological reactivity during early
infection, as shown previously and confirmed in this study and ELISA results only appear as
positive during the later stages of infection. With the completion of the genome sequence of
MAP K10, it became possible to identify potentially antigenic proteins at a full proteome scale
[6], and follow-up studies focusing on the ontogeny of the humoral response to MAP led to
identification of antigens marking the early stages of infection. For instance, in experimentally
Early diagnosis of Johne’s disease
PLOS ONE | https://doi.org/10.1371/journal.pone.0184373 September 1, 2017 12 / 18
infected cattle, some recombinant MAP proteins were identified on the basis of the humoral
immune response as early as 70 days after infection [36]. These identified antigens were also
recognized by sera from naturally infected cattle in the sub-clinical stage of Johne’s disease.
Other studies with MAP experimentally infected cattle showed that the antibody against the
recombinant protein (MAP1197) was detected 2–7 months earlier than a commercially avail-
able ELISA kit and even earlier than shedding in some cattle [14]. In naturally infected sheep
with mild histological lesions of paratuberculosis, more than half of the serum samples had
detectable antibody responses against recombinant MAP proteins, but no response to the
commercial ELISA [13]. Although promising, a comprehensive identification of the most
promising antigens during early stages of MAP infection was limited by several factors. First,
there was no well-characterized collection of serum samples from naturally infected animals
available to validate recombinant proteins and naturally infected host animals since these were
often not classified by different stages of sub-clinical infection. Second, it is difficult to screen
large numbers of recombinant proteins using standard ELISA or western blotting techniques,
as performed in previous studies. To overcome these limitations, during this investigation,
we used a total 180 serum samples from well characterized animals for screening of ~4,000
recombinant MTB proteins and identified reactive antigens at stages of early, middle, and late
infection. A total of 12 and 23 MAP orthologs were identified in the NH and F+E- groups,
respectively, although all cows in these two groups showed negative serological reaction based
on commercial ELISA tests on both serum and milk samples. Fifty-three MAP orthologs were
identified from F+E+. We compared the sensitivity and specificity of each identified ortholog
and tested if the sensitivity increased without losing specificity. As a result, 4 proteins were
selected from each group and combining these 4 antigens increased sensitivity without an
appreciable loss in specificity. As shown in Fig 4, sensitivity increased from 20.0–30.0% with a
single antigen to 60.0% with the 4 combined in NH, 26.7–36.7% to 63.3% in F+E-, and 33.0–
60.0% to 81.7% in F+E+. Compared to results with commercial ELISA methods, there is con-
siderable advantage for detection of reactive antigens with recombinant proteins during the
early and middle stages of infection because there was no detectable antibody response against
a crude mixture of antigens with commercial methods. However, at the late stage of infection
(F+E+) with high shedding levels, commercial ELISA methods showed higher sensitivity as
compared to recombinant proteins. This is consistent with previous studies showing that
ELISA has a higher sensitivity in animals with a heavier bacterial load (high shedders) com-
pared to low shedders [31]. Combined recombinant proteins showed increased sensitivity for
detection of infected cows in this study and we will plan to test more combination of different
proteins to improve the detection of infected animals in the future study.
While eight of the significantly reactive antigens identified with the MTB protein array in
our current investigation have also previously been reported to be recognized in sera from ani-
mals with subclinical and clinical infection [21–27, 29], a majority of the others have not, sug-
gesting that the protein microarray approach has considerably utility for diagnostic antigen
discovery. Further, our analyses suggest that the serological reactivity to MAP recombinant
proteins with ELISA is consistent with reactivity to MTB ortholgs on MTB arrays with a strong
correlation between reactivity to MTB orthologs on the protein array and to MAP proteins on
ELISA. These results are consistent with our earlier finding of concordance in scale and direc-
tion of serological reactivity between MTB and MAP arrays [17].
A majority of MAP proteins that were previously described as “non-antigenic” were also
not reactive in the MTB array, having either very low mean intensities or no significant differ-
ence between the infected and control groups. On the other hand, some of the proteins previ-
ously recognized as sero-reactive failed to be recognized as significantly reactive on the MTB
arrays. This could be due to the fact that: (i) the previously recognized MAP proteins had no
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homologs in MTB; (ii) identity of orthologs is too low for a MTB spot to be recognized by anti-
bodies against MAP orthologs; (iii) since there was only a small number of samples tested in
most of the previous studies, the results may not accurately reflect the true status; or (iv) some
antigens may have been identified in experimentally infected animals and there might be dif-
ferences in serological response between natural and experimentally infected animals. The util-
ity of the MTB array is limited when MAP proteins are either not represented or have low
levels of similarity to their MTB orthologs. For example, MAP2121c, a 35 kDa major mem-
brane protein (MMP) was identified as a reactive antigen in several MAP studies [36–39], has
no ortholog in MTB. Similarly, a cluster of MAP proteins from MAP0851-0865 have no ortho-
logs in MTB and are thus not included on the array even though several proteins in the cluster
were identified as antigenic in previous studies [12, 40].
It is important to note that all 8 proteins identified both in this MTB array study and previ-
ous studies were only found in the F+E+ except for one (MAP0210c, Rv0304), which was also
recognized in cows from the NH and F+E- groups. This is probably because the majority of
infected animals used in previous studies were at clinical or late sub-clinical stages, and the
majority of cows in this study (such as NH and F+E- groups) were at early or middle stages of
infection. About 80% of identified orthologs with the MTB microarray in this study have
never been tested in previous studies for their serological reactivity with a robust and represen-
tative serum bank, and many of these candidates will need to be expressed and added to the
MAP protein array for future studies.
In conclusion, the results of our studies have led to the identification of a large number of
promising candidates antigens that provide a strong framework for the future development of
the next generation of highly sensitive and specific diagnostic assays for the diagnosis of early
MAP infection in cattle and other susceptible hosts.
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